Clinical Trials Directory

Trials / Unknown

UnknownNCT05092802

The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment

An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of HLX208 for Refractory Primary Brain Tumors With BRAF Mutation

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Shanghai Henlius Biotech · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation

Conditions

Interventions

TypeNameDescription
DRUGHLX208450mg bid po

Timeline

Start date
2021-12-23
Primary completion
2023-05-30
Completion
2024-05-30
First posted
2021-10-26
Last updated
2022-05-03

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05092802. Inclusion in this directory is not an endorsement.